Added to YB: 2026-02-25
Pitch date: 2026-02-22
ABBV [neutral]
AbbVie Inc.
-5.21%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Market Cap
$368.4B
Pitch Price
$223.96
Price Target
230.00 (+8%)
Dividend
3.32%
EV/EBITDA
14.25
P/E
102.71
EV/Sales
6.88
Sector
Biotechnology
Category
N/A
New Fair Value Estimates - AbbVie Inc.
ABBV (update): End-of-year results confirm expectations. Fair value raised $5 to $230; currently fairly priced at $225. $18B FCF easily covers $2.5B interest expense, but high debt load remains a concern. Management should address debt reduction despite strong cash generation.
Read full article (1 min)